Markus Wartmann

9.1k total citations · 2 hit papers
89 papers, 6.9k citations indexed

About

Markus Wartmann is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, Markus Wartmann has authored 89 papers receiving a total of 6.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Oncology, 38 papers in Molecular Biology and 31 papers in Organic Chemistry. Recurrent topics in Markus Wartmann's work include Cancer Treatment and Pharmacology (42 papers), Synthetic Organic Chemistry Methods (25 papers) and Microtubule and mitosis dynamics (13 papers). Markus Wartmann is often cited by papers focused on Cancer Treatment and Pharmacology (42 papers), Synthetic Organic Chemistry Methods (25 papers) and Microtubule and mitosis dynamics (13 papers). Markus Wartmann collaborates with scholars based in Switzerland, United States and Germany. Markus Wartmann's co-authors include Roger J. Davis, John L. Knopf, Alice Lin, Lih‐Ling Lin, Karl‐Heinz Altmann, Terence O’Reilly, Doriano Fabbro, Paul M.J. McSheehy, Pascal Furet and Jürgen Mestan and has published in prestigious journals such as Nature, Cell and Journal of the American Chemical Society.

In The Last Decade

Markus Wartmann

89 papers receiving 6.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

cPLA2 is phosphorylated and activated by MAP kinase

1993 1.6k citations Markus Wartmann, Roger J. Davis et al. profile →
CDK 4/6 Inhibitors Sensitize PIK3CA Mutant Breast Cancer to PI3K Inhibitors

2014 351 citations Markus Wartmann, Alan Huang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Markus Wartmann Switzerland	39	3.8k	2.1k	1.1k	948	682	89	6.9k
Ching-Shih Chen United States	46	3.3k 0.9×	920 0.4×	545 0.5×	755 0.8×	558 0.8×	83	5.3k
Alexander J. Bridges United States	27	4.2k 1.1×	2.1k 1.0×	2.0k 1.8×	432 0.5×	248 0.4×	62	7.1k
Marco Falasca Australia	51	5.4k 1.4×	2.1k 1.0×	386 0.3×	1.6k 1.6×	545 0.8×	183	8.7k
Darren A.E. Cross United Kingdom	29	6.4k 1.7×	2.0k 0.9×	422 0.4×	1.1k 1.1×	341 0.5×	58	9.2k
Taebo Sim South Korea	31	3.5k 0.9×	1.1k 0.5×	951 0.8×	609 0.6×	222 0.3×	122	5.2k
Shi‐Yong Sun United States	56	7.2k 1.9×	2.7k 1.3×	586 0.5×	564 0.6×	507 0.7×	203	9.5k
Cristiano Ferlini Italy	41	3.0k 0.8×	1.7k 0.8×	512 0.5×	997 1.1×	279 0.4×	136	5.3k
David A. Gewirtz United States	53	4.4k 1.2×	2.2k 1.0×	384 0.3×	538 0.6×	415 0.6×	192	8.1k
Vivek M. Rangnekar United States	46	4.1k 1.1×	1.3k 0.6×	240 0.2×	879 0.9×	600 0.9×	119	6.0k
Jenny Bain United Kingdom	25	5.5k 1.5×	1.0k 0.5×	683 0.6×	702 0.7×	244 0.4×	29	7.4k

Countries citing papers authored by Markus Wartmann

Since Specialization

Citations

This map shows the geographic impact of Markus Wartmann's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Markus Wartmann with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Markus Wartmann more than expected).

Fields of papers citing papers by Markus Wartmann

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Markus Wartmann. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Markus Wartmann. The network helps show where Markus Wartmann may publish in the future.

Co-authorship network of co-authors of Markus Wartmann

This figure shows the co-authorship network connecting the top 25 collaborators of Markus Wartmann. A scholar is included among the top collaborators of Markus Wartmann based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Markus Wartmann. Markus Wartmann is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Laborde, Laurent, Dario Sterker, Hans-Peter Gschwind, et al.. (2018). Continuous low-dose infusion of patupilone increases the therapeutic index in mouse and rat tumour models. Anti-Cancer Drugs. 29(7). 691–701. 1 indexed citations

Weiss, Andreas, Diana Graus Porta, Christelle Stamm, et al.. (2017). Abstract 2103: NVP-FGF401: Cellular and in vivo profile of a novel highly potent and selective FGFR4 inhibitor for the treatment of FGF19/FGFR4/KLB+ tumors. Cancer Research. 77(13_Supplement). 2103–2103. 5 indexed citations

Michaloglou, Chrysiis, Typhaine Martin, Clara Delaunay, et al.. (2013). The Tyrosine Phosphatase PTPN14 Is a Negative Regulator of YAP Activity. PLoS ONE. 8(4). e61916–e61916. 69 indexed citations

Fritsch, Christine, Christian Schnell, Christian Chatenay‐Rivauday, et al.. (2012). Abstract 3748: NVP-BYL719, a novel PI3Kalpha selective inhibitor with all the characteristics required for clinical development as an anti-cancer agent. Cancer Research. 72(8_Supplement). 3748–3748. 15 indexed citations

Tiedt, Ralph, Pascal Furet, B.A. Appleton, et al.. (2011). A Drug Resistance Screen Using a Selective MET Inhibitor Reveals a Spectrum of Mutations That Partially Overlap with Activating Mutations Found in Cancer Patients. Cancer Research. 71(15). 5255–5264. 99 indexed citations

Boulay, Anne, Madlaina Breuleux, Christine Stephan, et al.. (2008). The Ret Receptor Tyrosine Kinase Pathway Functionally Interacts with the ERα Pathway in Breast Cancer. Cancer Research. 68(10). 3743–3751. 92 indexed citations

Manley, Paul W., Jürgen Mestan, Sandra W. Cowan‐Jacob, et al.. (2005). AMN107: Inhibitory profile against non-mutated and mutated forms of the Bcr-Abl tyrosine kinase. Cancer Research. 65. 1408–1408. 2 indexed citations

Wartmann, Markus, et al.. (2005). Scaffolds for Microtubule Inhibition through Extensive Modification of the Epothilone Template. Angewandte Chemie International Edition. 44(45). 7469–7473. 39 indexed citations

Wartmann, Markus, Marc Hattenberger, Melanie Müller, et al.. (2004). Preclinical pharmacological profile of ABJ879, a novel epothilone B analog with potent and protracted anti-tumor activity. Cancer Research. 64. 1256–1256. 8 indexed citations

10.

DiLea, Clifford, Markus Wartmann, Sauveur-Michel Maira, et al.. (2004). A PK-PD dose optimization strategy for the microtubule stabilizing agent ABJ879. Cancer Research. 64. 1184–1184. 1 indexed citations

11.

Rothermel, J. D., Markus Wartmann, Tse‐Ching Chen, & John Hohneker. (2003). EPO906 (epothilone B): A promising novel microtubule stabilizer. Seminars in Oncology. 30(3). 51–55. 46 indexed citations

12.

Nicolaou, K. C., Andreas Ritzén, Kenji Namoto, et al.. (2002). Chemical synthesis and biological evaluation of novel epothilone B and trans-12,13-cyclopropyl epothilone B analogues. Tetrahedron. 58(32). 6413–6432. 44 indexed citations

13.

Huwiler, Andrea, Markus Wartmann, H. van den Bosch, & Josef Pfeilschifter. (2000). Extracellular nucleotides activate the p38‐stress‐activated protein kinase cascade in glomerular mesangial cells. British Journal of Pharmacology. 129(3). 612–618. 43 indexed citations

14.

Olivier, Reynald, Isabelle Otter, Laurent Monney, Markus Wartmann, & Christoph Borner. (1997). Bcl-2 does not require Raf kinase activity for its death-protective function. Biochemical Journal. 324(1). 75–83. 19 indexed citations

15.

Huwiler, Andrea, et al.. (1997). Stimulation by extracellular ATP and UTP of the stress‐activated protein kinase cascade in rat renal mesangial cells. British Journal of Pharmacology. 120(5). 807–812. 40 indexed citations

16.

Wartmann, Markus, et al.. (1997). Negative Modulation of Membrane Localization of the Raf-1 Protein Kinase by Hyperphosphorylation. Journal of Biological Chemistry. 272(7). 3915–3923. 62 indexed citations

17.

Hynes, Nancy E., Nathalie Cella, & Markus Wartmann. (1997). Prolactin Mediated Intracellular Signaling in Mammary Epithelial Cells. Journal of Mammary Gland Biology and Neoplasia. 2(1). 19–27. 38 indexed citations

18.

Wartmann, Markus & Roger J. Davis. (1994). The native structure of the activated Raf protein kinase is a membrane-bound multi-subunit complex.. Journal of Biological Chemistry. 269(9). 6695–6701. 238 indexed citations

19.

Wartmann, Markus, David A. Jans, Peter J. Parker, et al.. (1991). Overexpression of the alpha-type protein kinase (PK) C in LLC-PK1 cells does not lead to a proportional increase in the induction of two 12-O-tetradecanoylphorbol-13-acetate-inducible genes.. PubMed. 2(6). 491–502. 15 indexed citations

20.

Northwood, I C, Fernando A. González, Markus Wartmann, David Raden, & Roger J. Davis. (1991). Isolation and characterization of two growth factor-stimulated protein kinases that phosphorylate the epidermal growth factor receptor at threonine 669. Journal of Biological Chemistry. 266(23). 15266–15276. 191 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact